

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
September 25, 2018**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

ImmunoGen, Inc.

File No. 0-17999 - CF#36699

ImmunoGen, Inc. submitted an application under Rule 24b-2 requesting an extension of prior grants of confidential treatment for information it excluded from the Exhibits to Forms 10-K filed on September, 27, 2000, August 28, 2006 and Forms 10-Q filed February 8, 2007, October 31, 2011 and August 4, 2017.

Based on representations by ImmunoGen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

| Exhibit | to Form | Filed on | Confidential Treatment Granted |
|----------------|----------------|--------------------|---------------------------------------|
| 10.31 | 10-K | August 28, 2006 | through August 19, 2025 |
| 10.32 | 10-K | August 28, 2006 | through October 31, 2025 |
| 10.1 | 10-Q | February 8, 2007 | through August 25, 2025 |
| 10.2 | 10-Q | February 8, 2007 | through August 28, 2025 |
| 10.1 | 10-Q | October 31, 2011 | through October 31, 2025 |
| 10.2 | 10-Q | October 31, 2011 | through October 31, 2025 |
| 10.52 | 10-K | September 27, 2000 | through October 31, 2025 |
| 10.2 | 10-Q | August 4, 2017 | through August 28, 2021 |

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary